AU2002356625A1 - N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors - Google Patents

N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors Download PDF

Info

Publication number
AU2002356625A1
AU2002356625A1 AU2002356625A AU2002356625A AU2002356625A1 AU 2002356625 A1 AU2002356625 A1 AU 2002356625A1 AU 2002356625 A AU2002356625 A AU 2002356625A AU 2002356625 A AU2002356625 A AU 2002356625A AU 2002356625 A1 AU2002356625 A1 AU 2002356625A1
Authority
AU
Australia
Prior art keywords
indole
group
mmol
different
harom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002356625A
Other languages
English (en)
Inventor
Tobias Braxmeier
Laura Casiraghi
Wolfgang Frohner
Sandra Gordon
Hans-Wolfgang Klafki
Barbara Monse
Silvia Muller
Hanno Roder
Heidi Sahagun-Krause
Pierfausto Seneci
Olivier Thillaye Du Boullay
Valerie Thillaye Du Boullay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nad AG
Original Assignee
Nad AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nad AG filed Critical Nad AG
Publication of AU2002356625A1 publication Critical patent/AU2002356625A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2002356625A 2001-12-17 2002-12-04 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors Abandoned AU2002356625A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10161940.5 2001-12-17
DE10161940A DE10161940A1 (de) 2001-12-17 2001-12-17 N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
PCT/EP2002/013753 WO2003051887A1 (en) 2001-12-17 2002-12-04 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2002356625A1 true AU2002356625A1 (en) 2003-06-30

Family

ID=7709523

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002356625A Abandoned AU2002356625A1 (en) 2001-12-17 2002-12-04 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors

Country Status (7)

Country Link
US (1) US7262215B2 (cg-RX-API-DMAC10.html)
EP (1) EP1456211A1 (cg-RX-API-DMAC10.html)
JP (1) JP2005518379A (cg-RX-API-DMAC10.html)
AU (1) AU2002356625A1 (cg-RX-API-DMAC10.html)
CA (1) CA2467780A1 (cg-RX-API-DMAC10.html)
DE (1) DE10161940A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003051887A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122526B2 (en) * 2000-10-31 2006-10-17 Nanosphere, Inc. Indolocarbazole anticancer agents and methods of using same
CL2007003693A1 (es) 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
US20100273769A1 (en) * 2009-01-26 2010-10-28 Hanno Roder Composition and method for the treatment of parkinson's disease
CN102557967A (zh) * 2011-12-28 2012-07-11 合肥科尚医药科技有限公司 一种盐酸氨溴索的制备方法
CN103113379A (zh) * 2013-03-12 2013-05-22 盛世泰科生物医药技术(苏州)有限公司 阿塞那平马来酸盐的合成工艺
CN117886799B (zh) * 2024-01-11 2025-07-29 浙江工业大学 一类靶向降解GSK-3β的蛋白降解靶向嵌合体化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
ATE175873T1 (de) * 1992-03-20 1999-02-15 Wellcome Found Weitere indolderivate mit antiviraler wirkung
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
GB9416467D0 (en) * 1994-08-13 1994-10-05 Wellcome Found Compounds for use in medicine
CN1285836A (zh) * 1997-12-31 2001-02-28 赛福伦公司 3′－差向异构的K－252a衍生物
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US7122526B2 (en) * 2000-10-31 2006-10-17 Nanosphere, Inc. Indolocarbazole anticancer agents and methods of using same
WO2003022861A1 (en) * 2001-09-13 2003-03-20 Bristol-Myers Squibb Company Process for the preparation of rebeccamycin and analogs thereof

Also Published As

Publication number Publication date
US7262215B2 (en) 2007-08-28
US20050075386A1 (en) 2005-04-07
EP1456211A1 (en) 2004-09-15
DE10161940A1 (de) 2003-07-03
JP2005518379A (ja) 2005-06-23
WO2003051887A1 (en) 2003-06-26
CA2467780A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
CA1337523C (en) Pyridonecarboxylic acids and antibacterial agents
SK9662001A3 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
NO20151245A1 (no) Nye kondenserte pyrrolokarbazolforbindelser
HUT67431A (en) Vinylen-or methylen-azaindol derivatives, pharmaceutical compositions containing the same and process for their production
EP1325011B1 (en) Methods and compounds for treating proliferative diseases
FR2563521A1 (fr) Derives de la 1,4-dihydro-4-oxonaphtyridine et leurs sels, procede pour leur production et agents antibacteriens les contenant
CN105683195A (zh) 新的喹啉取代的化合物
FR2876377A1 (fr) Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
US5405963A (en) Process for asymmetric total synthesis of camptothecin analogues
CN116547283A (zh) 取代的三环化合物
JP2009542585A (ja) キノリン誘導体、その調製方法、その使用、及びそれらを含んで成る医薬品
WO2003051887A1 (en) N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors
IL124287A (en) Method for preparing camptothecin derivatives and some novel intermediates thereof
US12459893B2 (en) Indole-ynone mediated benzoannulation process for the preparation of carbazoles, carbazomycin A, calothrixin B and staurosporinone
JP3497168B2 (ja) 抗腫瘍活性を有する２−アミノアルキル−５−アミノアルキルアミノ置換イソキノインダゾール−６−（２ｈ）−オン類
HUP0200529A2 (en) Optically pure camptothecin analogues, pharmaceutical compositions containing them and their use
KR0153530B1 (ko) 락탐 유도체의 제조 방법
EP1565473B1 (en) N,n-bridged, nitrogen-substituted carbacyclic indolocarbazoles as protein kinase inhibitors
EA007222B1 (ru) Способ получения кислотных солей гемифлоксацина
KR20040048926A (ko) 항암 활성을 갖는 폴리시클릭 화합물
Nakahara et al. Catalytic Hydrogenation of 8-Acyloxy-1-cyanoisoquinoline and Synthesis of 9-Methoxy-9-deethoxycribrostatin 6
JP2022537704A (ja) トリアゾロピリミジン化合物及びその塩、組成物と使用
FR2781482A1 (fr) Nouveaux derives de 8h-thieno-[2,3-b]pyrrolizine-8-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2001181281A (ja) 抗菌剤として有用なキノロン誘導体
MXPA05005261A (es) Procedimiento novedoso para la preparacion de compuestos imidazolilo.

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application